{
  "_id": "aecf9dc7dd948f9d3bed53112eab623d89c5b2e20a76001febd02cdb1cbcd892",
  "feed": "market-watch",
  "title": "Stock of psychedelics company MindMed slides 50% after it sells fresh shares; Mind Medicine Inc. recently reported positive data from a trial of LSD to treat anxiety",
  "text": "<p>Proceeds are expected to total about $30 million. RBC Capital Markets and Cantor were lead underwriters on the deal, with Oppenheimer &amp; Co. acting as co-manager.</p><p>MindMed MNMD stock enjoyed a rally of more than 50% in a single day in August, after it was named as a key holding by a young investor who made $110 million from meme stock Bed Bath &amp; Beyond BBBY.</p><p>Jake Freeman, a 20-year-old student, had purchased a 6.2% stake in the troubled retailer in July, and SEC filings show he profited royally. Freeman has interned for New Jersey hedge fund Volaris Capital, according to his LinkedIn profile.</p><p>For more, see: This investor made $110 million from trading Bed Bath &amp; Beyond — and he's a 20-year-old student</p><p>Freeman and his uncle Scott Freeman, a former pharmaceutical executive, had amassed an activist stake in MindMed, according to a Financial Times report from August. Freeman said he was planning to have a \"constructive\" dialogue with the board of Mind Medicine as he completed his studies in complex analysis and mathematical statistics at the University of Southern California. He's now studying for the GRE.</p><p>MindMed recently conducted a Phase 2 placebo-controlled, investigator-initiated trial of LSD as a treatment for anxiety and published a paper on the study in the peer-reviewed scientific journalBiological Psychiatry in September. The paper expanded on data offered in an oral presentation at the PYSCH Symposium in London in May,the company said in a statement.</p><p>Read also: 'Magic mushrooms' may help alcoholics drink 83% less — or stop drinking entirely, research suggests</p><p>The data showed a significant reduction in anxiety in patients who took LSD for up to 16 weeks, showing effects that lasted up to week 50. It also showed a reduction in depression. It was the first trial to use LSD on patients suffering from anxiety who did not have a life-threatening illness. The study was conducted in Switzerland — where psychedelic research is allowed — and involved 44 participants.</p><p>\"This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders,\" said Rob Barrow, chief executive of MindMed, in a statement.</p><p>The results \"are encouraging and supportive of our proprietary MM-120 product candidate in its potential to one day offer a therapeutic benefit for patients suffering from GAD (generalized anxiety disorder) after just a single-dose administration,\" he said.</p><p>The company is currently running a Phase 2b study.</p><p>Oppenheimer analyst Francois Brisebois said the results were encouraging, including the crossover data, which showed a decreasing trend in anxiety symptoms in patients once they moved from placebo to LSD. He reiterated his outperform rating on the stock and $52 price target. The stock is currently trading around $3.</p><p>MindMed has also launched a placebo-controlled study that seeks to evaluate the effects of MDMA-like substances in healthy volunteers.Those substances include MDA, Lys-MDMA and Lys-MDA.</p><p>The topic of psychedelics and their potential for use in mental-health disorders has become popular of late, in part boosted by a new Netflix documentary with Michael Pollan, \"How to Change Your Mind,\" which features promising stories of cancer patients losing their fear of death and veterans overcoming post-traumatic stress disorder. But researchers caution that there are still unknown risks to the therapy and that not every patient responds the same way.</p><p>Read now: The promise and the perils of the billion-dollar industry blossoming around psychedelic-assisted therapy</p><p>MindMed shares have fallen 85% in the year to date, while the S&amp;P 500 SPX has fallen 22%.</p><p>Stock of psychedelics company MindMed slides 50% after it sells fresh shares</p>",
  "published": "2022-09-28T17:26:00.000Z",
  "tags": [
    {
      "id": "US5949181045",
      "nexusId": "10031144",
      "name": "Microsoft Corporation",
      "offsets": []
    }
  ]
}